For most recent updates concerning Dr. Tseng and the Ocular Surface Center,
please visit the following link: http://osref.org/calendar-of-events.aspx

  • Dr. Tseng has obtained the FDA approval and NIH grant support to conduct Phase I clinical trial to determine the safety and efficacy of Transplantation of Ex Vivo Expanded Limbal Epithelial Stem Cells for Treating Limbal Stem Cell Deficiency.
  • Dr. Tseng received Senior Achievement Award from American Academy of Ophthalmology during the annual meeting at New Orleans, LA in 2004.
  • Dr. Tseng gave Kersley Lecture  at the annual meeting of Medical Contact Lens and Ocular Surface Association (MCLOSA) in London, UK, on Nov 19, 2004 and Oliver H. Dabezies Jr. M.D. Lecture at the annual meeting of Contact Lens Association of Ophthalmology (CLAO) in San Diego, CA, on Jan 22, 2005.
  • Dr. Tseng served as a member of the expert panel for Interagency Coordinating Committee on Validation of Alternative Methods (ICCVAM) sponsored by NIH, August 2004 - January 2005.
  • Dr. Tseng has summarized in a recent review explaining how amniotic membrane works in ocular surface reconstruction.
  • Dr. Tseng and his colleagues have discovered several new applications of amniotic membrane transplantation.  Amniotic membrane can help both the donor and recipient eyes receiving conjunctival limbal autograft and restore deep fornix during symblepharon lysis (especially in conjunction with intraoperative application of mitomycin C).
  • Dr. Tseng and his colleagues have discovered that conjunctivochalasis-induced dry eye an be differentiated from aqueous tear deficiency-induced dry eye, and that lipid tear deficiency due to meibomian gland dysfunction is the dominant cause for persistent dry eye following LASIK using kinetic analysis of tear interference images.
  • Dr. Tseng has been nominated as the regular member of the Study Section VISA by National Eye Institute, National Institute of Health
  • The Impression Cytology Laboratory of the Ocular Surface Center is the first in USA that has been certified by the State of Florida (No. 800017632) and CLIA (Clinical Laboratory Improvement Amendment 1998) (No.10D1004176) for diagnosing ocular surface failure in patients suffering difficult ocular surface diseases.
  • Dr. Tseng is licensed to compound special medications for patients suffering from severe dry eye including autologous serum drops.
  • Dr. Tseng has obtained the FDA approval to conduct Phase I clinical trial to determine the safety and efficacy of Transplantation of Ex Vivo Expanded Limbal Epithelial Stem Cells for Treating Limbal Stem Cell Deficiency.
  • Channel 7 interview of Dr. Tseng on Amniotic Membrane Transplantation for Ocular Surface Reconstruction (October 23, 2002).
  • Dr. Tseng received Chancellor's Award from Louisiana State University School of Medicine on November 7, 2002, and gave the lecture entitled "New Strategies of Ocular Surface Reconstruction". [Honors and Awards]